The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths globally, and Ghana is no ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

Overall, the one-time LDCT diagnostic performance in the non-risk-based screening population had a sensitivity of 96.6%, a ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Oncology experts discuss de-escalation strategies that can reduce toxicity, save a billion in healthcare costs, and make lung ...

The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

RxDx Device for non-small cell lung cancer has received Breakthrough Device Designation from the U.S. Food and Drug ...

Despite AstraZeneca’s falling share price today, this writer believes the London-listed pharmaceutical giant could be worth a ...